Phio Pharmaceuticals Corp./$PHIO
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Ticker
$PHIO
Sector
Primary listing
Employees
6
Headquarters
Website
PHIO Metrics
BasicAdvanced
$13m
-
-$1.40
0.81
-
Price and volume
Market cap
$13m
Beta
0.81
52-week high
$4.19
52-week low
$0.81
Average daily volume
145k
Financial strength
Current ratio
18.318
Quick ratio
17.927
Profitability
EBITDA (TTM)
-11.512
Management effectiveness
Return on assets (TTM)
-46.65%
Return on equity (TTM)
-76.36%
Valuation
Price to book
0.76
Price to tangible book (TTM)
0.76
Price to free cash flow (TTM)
-0.787
Free cash flow yield (TTM)
-127.03%
Free cash flow per share (TTM)
-1.372
Growth
Earnings per share change (TTM)
-64.07%
3-year earnings per share growth (CAGR)
-75.76%
PHIO News
AllArticlesVideos
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Newsfile Corp·1 month ago
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
Newsfile Corp·2 months ago
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
Newsfile Corp·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs